< Volver

Resumen

Metabolic Syndrome: from the clinical to the molecular

VOLUMEN 5 - NÚMERO 1 / Enero - Marzo (Artículo de Revisión)


Alberto Rodríguez-Gutiérrez, Servicio de Endocrinología, Hospital General de Zona 3 Delegación Querétaro, Instituto Mexicano del Seguro Social, Ciudad de México, México
Elida Yolanda García-Espinosa, Servicio de Endocrinología, Especialidades Médicas Ángeles de Tehuacán,
Mario A. Molina-Ayala, Servicio de Endocrinología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
Aldo Ferreira-Hermosillo, Servicio de Endocrinología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Ciudad de México, México

Metabolic syndrome prevalence has increased worldwide. In Mexico, it is 46% according to the criteria of the American Heart Association/ National Heart Blood and Lung Institute, but varies depending on the criteria used for its diagnosis. This syndrome is a well-documented cause of increased cardiovascular diseases like coronary heart disease or stroke as well as cardiovascular mortality. The main physiopathological mechanism involved in its development is the insulin resistance, whose definition seems to be simple, but it implies molecular changes at receptor, pre-receptor and post-receptor levels, caused by certain molecules as free fatty acids or cytokines secreted by adiposse tissue in obese patients. The purpose of this review is to describe current definitions of metabolic syndrome as well as novel aspects of insulin secretion and theories about physiopathologic mechanisms for insulin resistance with special emphasis in molecular aspects.

Palabras clave: Metabolic syndrome. Obesity. Resistance to insulin.

Artículo completo en PDF